The use of newly discovered TLS pols inhibitors, or p53 reactivation, are solid fields to be explored, while for example, the use of established senotherapeutics (senolytic and senomorphic drugs) have the theoretical and experimental background necessary to make them good candidates as co-adjuvants to the standard GBM therapy [212,312,313]. Here, TP53 is linked to glioblastoma.